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Background
Treatment of patients with JIA with DMARDs is started
immediately after diagnosis, resulting in more effective
suppression of disease activity. TNF blockers are recom-
mended in cases of active JIA after the unsuccessful use
of DMARDs. The exact role of these agents in the treat-
ment of early-stage JIA is unknown.
Objective
To evaluate the efficacy of infliximab in patients (n=100)
with early and long-standing JIA.
Methods
100 (60 with early and 40 with long-standing JIA)
patients who didn’t respond to DMARDs received inflix-
imab 6-7 mg/kg q8wks. Evaluation of efficacy included
30%, 50% and 70% improvement by the ACR-pedi cri-
teria and remission.
Results
At 54 week 100% and 87.5% patients with early and
long-standing JIA respectively achieved at least 50%
response. After 2 years ACR-Pedi 70/90 response to
infliximab was recorded in all patients with early JIA
and 100%/88.9% of patients with long-standing JIA
respectively. At weeks 54 following infliximab treatment,
89% and 60% of patients with early and long-standing
JIA achieved remission. At the end of the second year,
remission was reported in 97% of children with early
JIA and 72% of patients in the second group. 34% of the
patients discontinued due to an adverse event, mainly
lack of efficacy (23 patients) and hypersensitivity reac-
tions (11 patients).
Conclusions
This 2-years study suggest using IFX as initial treatment
for patients with recent onset JIA is more effective than
reserving it for patients with long-standing JIA. No dif-
ference between groups in adverse events and secondary
inefficacy were observed.
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